Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 30, 2000 (53-week fiscal year)
Business Overview: The largest distributor of healthcare products and services to office-based practitioners in North America and Europe. Operations are divided into two segments: Healthcare Distribution (dental, medical, veterinary, international) and Technology (practice management software). The company serves over 400,000 customers globally.
Key Financial Metrics
| Metric | 2000 (in thousands) | 1999 (in thousands) |
|---|---|---|
| Net Sales | $2,381,721 | $2,284,544 |
| Gross Profit | $647,901 | $608,596 |
| Gross Margin | 27.2% | 26.6% |
| Operating Income | $112,589 | $105,765 |
| Net Income | $56,749 | $50,312 |
| Diluted EPS | $1.35 | $1.21 |
| Operating Cash Flow | $152,994 | $56,493 |
| Total Debt | $276,693 | $363,624 |
| Working Capital | $423,547 | $428,429 |
| Cash and Equivalents | $58,362 | $26,019 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4.3% to $2.38 billion, driven primarily by an 11.1% increase in the Medical segment ($79.7 million) and a 2.5% increase in the Dental segment. International sales declined 3.3% due to unfavorable foreign exchange rates.
- Profitability: Net income rose 12.8% to $56.7 million. Gross margin improved to 27.2% from 26.6%, aided by sales mix changes.
- Restructuring: The company incurred one-time restructuring costs of $14.4 million ($9.3 million after-tax) related to a plan to eliminate approximately 300 positions (5% of workforce) and close facilities to improve efficiency.
- Debt Reduction: Total debt decreased by approximately $87 million year-over-year, with net debt repayments of $84.5 million in 2000.
- Cash Flow: Operating cash flow more than doubled to $153.0 million, driven by higher profitability and improved working capital management (decreases in receivables and inventory).
Guidance, Outlook, and Risks
- Restructuring Outlook: Management expects the 2000 restructuring plan to yield annual pre-tax cost savings of approximately $20.0 million ($12.0 million after-tax), or $0.29 per diluted share.
- Capital Expenditures: The company expects to invest over $45.0 million in the coming year to modernize facilities and infrastructure.
- Dividend Policy: The company does not anticipate paying cash dividends in the foreseeable future, intending to retain earnings for expansion.
- Legal Contingencies:
- Product Liability: Defendant in approximately 68 cases, including 52 involving latex glove allergies and 9 involving "Phen/fen" drugs. Management expects indemnification from manufacturers.
- Class Action: Pending appeal in the Texas Supreme Court regarding a class action suit involving practice management software (Easy Dental). The trial on merits is stayed pending the appeal.
- Market Risks: Exposure to foreign currency fluctuations (hedged via forward contracts) and interest rate changes (hedged via swaps and caps). The company does not hedge long-term translation exposure.
Investor Verification Checklist
- Restructuring Savings: Verify if the projected $20 million in annual pre-tax savings from the restructuring plan are being realized in subsequent quarters.
- Legal Exposure: Monitor the status of the Texas Supreme Court appeal regarding the Easy Dental class action and the resolution of latex glove liability claims.
- International Performance: Assess whether the decline in international sales was solely due to currency translation or if underlying market share was lost.
- Debt Covenants: Review compliance with financial covenants in the revolving credit agreement and senior notes, particularly regarding leverage and interest coverage ratios.
- Acquisition Integration: Evaluate the performance of recent acquisitions (GIV, Heiland Group) and the realization of contingent consideration payments.